TRANSCEND-CLL-004: liso-cel in CLL Published 2021-06-21 Download video MP4 360p Recommendations 03:50 The real-world effectiveness of venetoclax-based therapy after BTKis in patients with CLL 03:37 Biomarker analysis of luspatercept versus epoetin alfa in LR-MDS in the Phase III COMMANDS study 04:14 A pilot study of axi-cel in primary and secondary CNS lymphomas 02:01 Treating triple refractory CLL in patients with HIV 03:35 Precision medicine and Oxford, challenges and opportunities - Sir John Bell GBE 02:34 Results from a single-cell spatial analysis of the renal AL amyloidosis immunome 01:44 The outcomes of patients with AL amyloidosis and end-stage renal disease 01:37 A prospective trial of radiation-free chemotherapy in high- and low-risk HL 01:57 Proteome dynamics during normal and malignant hematopoietic stem cell expansion 04:10 Reigniting Hope to Reclaim Movement 18:40 Matthew Perry's Death From Ketamine Explained (Is It Safe For You?) 08:32 Peter Dauvergne (University of British Columbia, Vancouver, Canada) 03:23 Ivaylo Iaydjiev, MSc in Global Governance & Diplomacy (2012-13), University of Oxford 03:57 What is chronic lymphocytic leukaemia? 01:52 How do we know that bacteria were around billions of years ago? 13:50 4 Tricks for when doctors gaslight you - Dr. Kaveh LIVE 04:45 Orthopaedics in Oxford 05:50 Immunotherapy and breast cancer: how does it work? 03:00 What are the urinary symptoms of BPH? 03:13 3 things to remember when diagnosing patients with MGUS Similar videos 01:12 Primary analysis of TRANSCEND-CLL-004: liso-cel in R/R CLL 07:52 Dr. Siddiqi on Liso-Cel in the TRANSCEND CLL 004 Study 03:09 Liso-cel induces rapid uMRD: TRANSCEND-CLL-004 update 03:17 TRANSCEND-CLL-004 study update: safety and efficacy of liso-cel in R/R CLL 01:07 The current status of liso-cel in CLL and updates from the TRANSCEND-CLL-004 trial 03:12 Liso-cel in R/R CLL: 24-month follow-up of TRANSCEND-CLL-004 03:34 TRANSCEND-CLL-004: pivotal in the FDA approval of liso-cel for R/R CLL 01:16 TRANSCEND CLL-004 update from EHA: liso-cel for R/R CLL 04:47 Liso-Cel in CLL 02:32 MRD status after liso-cel in the TRANSCEND-CLL-004 trial 04:26 TRANSCEND-CLL-004: lisocabtagene maraleucel in CLL 01:29 TRANSCEND-CLL-04: 18-month follow-up of liso-cel for R/R CLL 04:20 Extended follow-up of the TRANSCEND-CLL-004 monotherapy cohort 02:19 Dr. Siddiqi on the Safety Profile of Liso-Cel in the TRANSCEND CLL 004 Trial 03:46 TRANSCEND CLL 004 study 00:34 Copy of Dr. Siddiqi on the Safety Profile of Liso-Cel in the TRANSCEND CLL 004 Trial 01:36 Dr. Siddiqi on the Results of the TRANSCEND CLL 004 Trial 03:53 Latest updates on liso-cel for R/R CLL/SLL 01:14 Andre Goy, MD, on the TRANSCEND-CLL-004 data investigating the use of CAR-T cell therapy DLBCL More results